An investigational oral Janus kinase (JAK) inhibitor failed to meet most primary endpoints in a phase III trial of patients ...

The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral and topical Janus kinase (JAK) inhibitors across the seven major ...

In October 2024, Pelabresib in combination with ruxolitinib showed benefit in treating patients with JAK Inhibitor-Naïve Myelofibrosis significantly reduced splenomegaly, and improved anemia that has ...

Targeted drugs for rheumatoid arthritis (RA) are not created equal when it comes to pain relief, a retrospective study from ...

The researchers found nearly half (47%) of the posts focused on efficacy, while 16% discussed adverse effects such as acne, ...

Novel macrocyclic heteroaryl derivatives acting as non-receptor tyrosine-protein kinase TYK2 and/or JAK1 and/or JAK2 inhibitors have been reported in a Hangzhou Highlightll Pharmaceutical Co. Ltd.

Today, some of the most innovative therapies in development are Janus kinase (JAK) inhibitors, and the latest ‘game changer’ Tyrosine kinase 2 (TYK2) inhibitors. The healthcare press has ...

PhD Defense: Effectiveness and safety of dupilumab and JAK-inhibitors in daily practice; Optimizing Treatment for Atopic Dermatitis ...

The biologic DMARDs rituximab and abatacept were associated with an increased risk for incident cancers in patients with RA ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window WASHINGTON -- Patients taking Janus kinase (JAK) inhibitors for rheumatoid arthritis (RA) may not have to worry so much ...